Expand LLY Menu
LLY MENU

LLY Latest Press Releases

-- November 20, 2024 --

Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS Globe Newswire 5:00 AM

-- November 19, 2024 --

Lilly announces changes on board of directors PRNewswire 4:30 PM

-- November 18, 2024 --

Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose PRNewswire 2:52 PM

-- November 16, 2024 --

Lilly's tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction (HFpEF) and obesity PRNewswire 10:00 AM

-- November 13, 2024 --

Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks PRNewswire 5:05 PM
Asha Therapeutics Awarded Barnett Drug Development Grant by the ALS Association to Advance Novel Intra-Molecular Glue Inhibitor of SARM1 to Clinic and Announces Appointment of Disarm Therapeutics' Founders to Company's Scientific Advisory Board Business Wire 9:30 AM

-- November 5, 2024 --

Lilly announces details of presentations at the 2024 American Society of Hematology (ASH) Annual Meeting PRNewswire 9:04 AM

-- November 1, 2024 --

Lilly to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium PRNewswire 5:30 PM

-- October 30, 2024 --

Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products PRNewswire 6:45 AM

-- October 29, 2024 --

Modified Titration of Donanemab Demonstrated Reduction of ARIA-E in Early Symptomatic Alzheimer's Disease Patients in Phase 3b study PRNewswire 12:15 PM

-- October 28, 2024 --

Lilly declares fourth-quarter 2024 dividend PRNewswire 11:31 AM
Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both ulcerative colitis and Crohn's disease PRNewswire 6:45 AM

-- October 25, 2024 --

Lilly's EBGLYSS (lebrikizumab-lbkz) demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with moderate-to-severe atopic dermatitis who discontinued dupilumab PRNewswire 6:45 AM

-- October 23, 2024 --

Lilly's Kisunla (donanemab-azbt) Receives Marketing Authorization in Great Britain for the Treatment of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in Adult Patients Who Are Apolipoprotein E ?4 Heterozygotes or Non-Carriers PRNewswire 5:00 AM

-- October 16, 2024 --

Lilly confirms date and conference call for third-quarter 2024 financial results announcement PRNewswire 10:00 AM
Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies PRNewswire 7:30 AM

-- October 14, 2024 --

Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease PRNewswire 6:45 AM

-- October 2, 2024 --

Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials PRNewswire 7:30 AM

-- September 25, 2024 --

New data show Lilly's EBGLYSS (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis PRNewswire 6:45 AM

-- September 24, 2024 --

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse Globe Newswire 8:45 AM
Lilly's Kisunla (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease PRNewswire 6:00 AM

-- September 13, 2024 --

FDA Approves Lilly's EBGLYSS (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis PRNewswire 4:08 PM

-- September 12, 2024 --

Lilly expands manufacturing footprint in Ireland with $1.8 billion investment PRNewswire 5:30 AM

-- September 10, 2024 --

With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes PRNewswire 11:57 AM
Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes PRNewswire 11:18 AM

-- September 9, 2024 --

Lilly appoints Lucas Montarce as executive vice president and chief financial officer PRNewswire 6:45 AM

-- September 5, 2024 --

In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin PRNewswire 6:45 AM

-- September 4, 2024 --

Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries PRNewswire 6:00 AM

-- August 27, 2024 --

Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity PRNewswire 6:45 AM

-- August 22, 2024 --

Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference PRNewswire 10:00 AM

-- August 20, 2024 --

Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight PRNewswire 6:45 AM

-- August 16, 2024 --

Lilly announces retirement of Marschall S. Runge from its Board of Directors PRNewswire 4:15 PM
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease PRNewswire 8:39 AM

-- August 13, 2024 --

Lilly opens state-of-the-art research and development center in the Boston Seaport PRNewswire 8:00 AM

-- August 8, 2024 --

Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses Globe Newswire 4:00 PM
Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion PRNewswire 6:45 AM

-- August 6, 2024 --

Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses Business Wire 4:00 PM
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033 Globe Newswire 8:30 AM

-- August 2, 2024 --

Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses Globe Newswire 4:00 PM

-- August 1, 2024 --

Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity PRNewswire 6:45 AM

-- July 29, 2024 --

Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses Business Wire 4:00 PM

-- July 28, 2024 --

Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses Globe Newswire 4:00 PM

-- July 25, 2024 --

Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement PRNewswire 10:00 AM
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected Globe Newswire 8:30 AM

-- July 19, 2024 --

MORPHIC HOLDING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Morphic Holding, Inc. - MORF Business Wire 5:59 PM

-- July 9, 2024 --

MORPHIC HOLDING INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Morphic Holding, Inc. - MORF Business Wire 5:32 PM

-- July 8, 2024 --

GordonMD Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with Lilly Business Wire 8:15 AM
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease PRNewswire 6:45 AM

-- July 2, 2024 --

Lilly's Kisunla (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease PRNewswire 1:35 PM

-- June 25, 2024 --

Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria PRNewswire 10:00 AM

-- June 24, 2024 --

Lilly Declares Third-Quarter 2024 Dividend PRNewswire 11:30 AM